Omalizumab Before Onset of Exacerbations
NCT05332067
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
OBOE is a prospective, pilot, parallel group RCT with the overall aim of examining the effect of a single dose of anti-IgE (omalizumab) vs. placebo administered at the onset of URIs in the fall season among highly exacerbation-prone, urban, and atopic youth aged 6-17 years with persistent asthma. OBOE will recruit and randomize participants over 3 years (3 annual cohorts of participants). Recruitment for each of the yearly cohorts of OBOE will begin in February.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma in Children
- Atopy
- Viral Upper Respiratory Infection
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Children's National Research Institute
- Last updated on ClinicalTrials.gov
- July 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Children's National Hospital · Washington D.C., DC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.